BGB-58067-101: A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors

The purpose of this study is to test if study drug (BGB-58067) is safe and tolerable, test how your body processes the study drug, and test if it works in patients with advanced solid tumor who have MTAP deficiency, including those with a loss of MTAP or no MTAP expression, when it is given on its own.